About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Stem Cell Therapy in Duchenne Muscular Dystrophy | Clinical Trials | Clareo Health

Back to clinical trial search

WITHDRAWNPhase 1NCT02241434

Stem Cell Therapy in Duchenne Muscular Dystrophy

The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.

Lead sponsor: Neurogen Brain and Spine Institute•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Neurogen Brain and Spine Institute

Age

3 - 25 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•age group of 3-25 years
•Duchenne muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion Criteria

•presence of respiratory distress
•presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
•malignancies
•acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30%
•pregnancy or breastfeeding

Related studies

A Remote Study Using Technology to Assess Outcomes in DMD

NCT07423026 · Duchenne Muscular Dystrophy (DMD)

RECRUITINGPhase 3

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

NCT07160634 · Duchenne Muscular Dystrophy

RECRUITINGPhase 1

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

NCT06817382 · Duchenne Muscular Dystrophy

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

NCT06839469 · Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)

RECRUITINGPhase 1/2

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862 · Duchenne Muscular Dystrophy (DMD)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 25, 2018Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE1

Enrollment—

Start dateJan 2009

Last updatedOct 25, 2018

Condition

Duchenne Muscular Dystrophy

Locations shown

Neurogen brain and spine institute

Navi Mumbai, Maharashtra

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 25, 2018Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions